Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S ADR (NY: NVO )

135.05 -2.01 (-1.47%)
Streaming Delayed Price Updated: 9:57 AM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
57 58 Next >
These 2 carnivore dining stocks gaining on the Ozempic craze
Ozempic and GLP-1 parallel the artificial intelligence (AI) mania, but it has also propelled "carnivore" restaurants like the two we feature here. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
This Warren Buffett Stock Is On The Cusp Of Joining The $1 Trillion Club
Berkshire Hathaway is just below a $1 trillion market cap. 
Via Investor's Business Daily
Why the quality investor may take a look at NYSE:NVO.
Should you consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for quality investing? 
Via Chartmill
Balancing Dividends and Fundamentals: The Case of NYSE:NVO.
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for dividend investing? 
Via Chartmill
2 No-Brainer Biotech Stocks to Buy Right Now
These stocks are used to beating the market. 
Via The Motley Fool
DexCom: A Winner In Diabetes Management
Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
Via Talk Markets
1 Wall Street Analyst Thinks Novo Nordisk Stock Is Going to $140. Is It a Buy?
There's little reason to think that a big correction is in store. 
Via The Motley Fool
Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge, Goldman Sachs Forecasts
Goldman Sachs predicts a potential 1% GDP boost from GLP-1 agonists market. Novo Nordisk and Eli Lilly lead, with analysts foreseeing 10-70 million users by 2028. AI-powered drug discovery and... 
Via Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
7 Analysts Assess Novo Nordisk: What You Need To Know
Via Benzinga
Novo Nordisk Unusual Options Activity For February 14
Via Benzinga
NYSE:NVO is not too expensive for the growth it is showing.
Investors seeking growth at a reasonable cost should explore NYSE:NVO. 
Via Chartmill
Move Over Magnificent 7, Say Hello to the GRANOLAS
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
Weight-Loss Drugs Vs. Conagra Foods: Company Optimistic Amid Shifting Consumer Demands Influenced By Hunger Suppressing
Conagra Brands' optimistic outlook at a Conference addressing concerns about weight-loss drugs impacting U.S. food companies. Executive backs positivity with Numerator data, citing an 8% rise in... 
Via Benzinga
3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024
Predicting top sectors isn't easy; we usually identify them only in hindsight, but these three stock market segments are rapidly rising. 
Via InvestorPlace
3 Cheap Dividend Stocks to Snatch Up Now
Cheap dividend stocks offer rebound upside paired with an income source that is difficult to beat for most investors. 
Via InvestorPlace
Ozempic Effect: Food Industry Feels The Heat As Weight-Loss Drugs Get Popular, Investors Call For Menu Makeovers
A survey conducted by Bloomberg Markets Live revealed that nearly 75% of the 303 respondents believe that companies selling unhealthy foods should recalibrate their business models. This could involve... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.
It may be best known for its diabetes treatment, Ozempic, but Novo Nordisk has a host of other blockbuster drugs, too. 
Via The Motley Fool
Wealth Generators: 3 Growth Stocks You’ll Regret Not Buying in 2024
Novo Nordisk (NVO), Caterpillar (CAT), and First Solar (FSLR) are the 3 best growth stocks you'll regret now buying in 2024! 
Via InvestorPlace
22 Blue-Chip European Dividend Growth Stocks
A discussion of insights on European dividend growth stocks. 
Via Talk Markets
Meet the Next Trillion-Dollar Companies: Our Top 7 Picks
These future trillion-dollar stocks are on their way to mythic valuation, supported by strong underlying fundamentals and prospects. 
Via InvestorPlace
UK Becomes First Major Market for Eli Lilly's Mounjaro Prefilled Pen For Tackling Obesity
Eli Lilly's popular obesity and diabetes drug, Mounjaro (tirzepatide), hits the UK market this week. Superdrug and Simple Pharmacy offer accessible prescriptions for NHS and private patients. 
Via Benzinga
S&P 500's surge to new highs: Bull trap hiding in plain sight?
Nvidia and Meta lead the S&P 500 rally, but there's cause for concern about a potential bull trap amid market volatility and a pivot to stable dividend payers. 
Via MarketBeat
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy
Rise of adolescent usage of Novo Nordisk's Wegovy for pediatric obesity. Surging demand among families, but concerns linger on the impact of weight-loss drugs on growing children's development. 
Via Benzinga
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year
Don't let the stock's high price deceive you -- Novo Nordisk can still make for a great investment. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
57 58 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.